SLX1 silencing overcomes Olaparib resistance in metastatic castration-resistant prostate cancer by disrupting SLX4-mediated DNA repair complexes
This study highlights SLX1 as both a prognostic marker and potential therapeutic target to enhance PARPi efficacy in advanced prostate cancer. Targeting SLX1 may be a promising strategy to overcome Olaparib resistance in mCRPC patients with homologous recombination deficiency.
Authors
- Yi Lei (ORCID: https://orcid.org/0000-0002-0857-6317)
- Xin Zhao (ORCID: https://orcid.org/0000-0002-1748-2275)
- Shiyun Feng (ORCID: https://orcid.org/0009-0002-4834-9220)
- Xiaoping Nitie
- Shibu Muluo
Institutions
- Affiliated Hospital of Southwest Medical University (CN)
- First Affiliated Hospital of Sichuan Medical University (CN)
- Arkana Laboratories (US)
- Key Laboratory of Guangdong Province (CN)
- The People's Hospital of LinXia (CN)
- Xiangshan County First People's Hospital (CN)
Publication Details
- Journal
- Cancer Biology & Therapy
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1080/15384047.2025.2545062
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05